TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21786187

Group type: EXPERIMENTAL
Intervention: Platelet number
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Platelet secretion of ATP
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Expression of P-selectin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Monocyte- and endothelium-derived microvesicles
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Platelet-derived and total procoagulant phosphatidylserine-positive microvesicles
Number of subjects: 118
Study: 18206146

Group type: EXPERIMENTAL
Intervention: Ionomycin for artificial oocyte activation (10 muM for 10 minutes)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no artificial oocyte activation)
Number of subjects: 87
Study: 17163361

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 12943178

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 100
Study: 11068398

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9586474

Group type: EXPERIMENTAL
Intervention: Mk II self‐tapping implants
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard implants
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mandibular implants
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Maxillary implants
Number of subjects: 103
Study: 8466895

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: racemic alpha-tocopherol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both vitamin E groups
Number of subjects: 16
Study: 3544084

Group type: EXPERIMENTAL
Intervention: MOPP (mustine, Oncovin, procarbazine, prednisone)
Number of subjects: 299

Group type: COMPARATOR
Intervention: LOPP (Leukeran substituted for mustine)
Number of subjects: 299
Study: 31385800

Group type: EXPERIMENTAL
Intervention: Low-molecular weight iron dextran (1 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 60
Study: 29332050

Group type: EXPERIMENTAL
Intervention: Supplemental L (10 mg), MZ (10 mg), and Z (2 mg) daily for 12 months
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 26610430

Group type: EXPERIMENTAL
Intervention: Testosterone (1000 mg T undecanoate)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 25445074

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for late-life GAD, 10 sessions
Number of subjects: 150
Study: 22245877

Group type: EXPERIMENTAL
Intervention: Antimuscarinic agent (solifenacin)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No antimuscarinic agent
Number of subjects: 33
Study: 21158371

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection
Number of subjects: 4
Study: 17323071

Group type: EXPERIMENTAL
Intervention: High-fat meal followed 2 h later by a bout of 1 h moderate (60% max HR) exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-fat meal alone
Number of subjects: 10
Study: 15930936

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized total knee arthroplasties
Number of subjects: 18

Group type: COMPARATOR
Intervention: Posterior cruciate-retaining total knee arthroplasties
Number of subjects: 18
Study: 12908378

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1000000
Study: 10561188

Group type: EXPERIMENTAL
Intervention: Surgically implanted venous access port (Port‐a‐Cath; Pharmacia, Canada Inc, Montreal, Québec, Canada)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard peripheral venous access
Number of subjects: 119
Study: 8721162

Group type: COMPARATOR
Intervention: Control experiment - reproduction by pointing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiment - visual reproduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doubling-distance experiment - reproduction by pointing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doubling-distance experiment - visual reproduction
Number of subjects: 0
Study: 1712835

Group type: EXPERIMENTAL
Intervention: Etidronate disodium (EHDP) 5 mg/kg/d
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 7040950

Group type: EXPERIMENTAL
Intervention: Oral glucose‐electrolyte solution containing 90 mmol of sodium per liter
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Oral glucose‐electrolyte solution containing 50 mmol of sodium per liter
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard intravenous therapy
Number of subjects: 146
Study: 31658335

Group type: EXPERIMENTAL
Intervention: RA + FM
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: RME + FM (pubertal group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: RME + FM (postpubertal group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SARME + FM
Number of subjects: 42
Study: 29529222

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 3293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3293
Study: 27039178

Group type: EXPERIMENTAL
Intervention: TXT2BFiT mHealth program (3-month intervention with 6-month maintenance)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TXT2BFiT mHealth program
Number of subjects: 250
Study: 23985706

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tenofovir (TDF)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 148
Study: 22348071

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with EMLA cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dry wicks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wet wicks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 50
Study: 20545664

Group type: EXPERIMENTAL
Intervention: Venous bubble trap in MECC system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard minimized extracorporeal circuit without venous bubble trap
Number of subjects: 40
Study: 17426329

Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 15781142

Group type: EXPERIMENTAL
Intervention: Commercially available sports drink (Test)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mineral water (Control)
Number of subjects: 10
Study: 12225711

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 3156
Study: 10217908

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 21
Study: 7818159

Group type: EXPERIMENTAL
Intervention: Continuous-wave Doppler ultrasound
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Continuous-wave Doppler examination
Number of subjects: 116
Study: 2187176

Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 160
Study: 94008

Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment in one eye
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 42
Study: 31144720

Group type: EXPERIMENTAL
Intervention: Antibiotic catheter lead coverage (group A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No antibiotic protection (group B)
Number of subjects: 19
Study: 31488113

Group type: EXPERIMENTAL
Intervention: Post-scenario debriefing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stop-and-go debriefing
Number of subjects: 50
Study: 28724365

Group type: COMPARATOR
Intervention: Low-dose rituximab (500 mg on days 1 and 15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leflunomide (10-20 mg/day)
Number of subjects: 40
Study: 26812182

Group type: EXPERIMENTAL
Intervention: BoNT/B
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 24284971

Group type: EXPERIMENTAL
Intervention: Biodegradable packing (Nasopore)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nondegradable packing (Merocel)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both biodegradable and nondegradable packing
Number of subjects: 56
Study: 23082538

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.2 mg/kg s.c.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.5 mg/kg s.c.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Buprenorphine (0.1 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Buprenorphine (1 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (0.9% s.c. equivalent volume)
Number of subjects: 11
Study: 18332063

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programme
Number of subjects: 525

Group type: COMPARATOR
Intervention: Centre-based cardiac rehabilitation programme
Number of subjects: 525
Study: 17463114

Group type: EXPERIMENTAL
Intervention: CT‐free computer‐assisted navigation system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 100
Study: 15589858

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11726411

Group type: EXPERIMENTAL
Intervention: Remifentanil with nitrous oxide and oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane with nitrous oxide and oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 0
Study: 9394721

Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 76
Study: 8424424

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3324596

Group type: EXPERIMENTAL
Intervention: Linear incision plus curettage under antibiotic cover
Number of subjects: 50

Group type: COMPARATOR
Intervention: Deroofing and drainage
Number of subjects: 50
Study: 29410559

Group type: EXPERIMENTAL
Intervention: Flexi‐Bar exercise program with vibration stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: General physical therapy
Number of subjects: 30
Study: 27207495

Group type: EXPERIMENTAL
Intervention: Treadmill walking combined with obstacle-crossing (30 min/day, 5 times/week, for 4 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (30 min of active/passive exercises and 30 min of gait training in the form of treadmill walking)
Number of subjects: 29
Study: 25677846

Group type: EXPERIMENTAL
Intervention: worst side improvement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: best side improvement
Number of subjects: 28

Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 28
Study: 23782918

Group type: COMPARATOR
Intervention: Conventional Education (CE)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Conventional Education + Motivational Interviewing (CE+MI)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Conventional Education + Motivational Interviewing + Risk Assessment (CE+MI+RA)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: All groups (CE, CE+MI, CE+MI+RA)
Number of subjects: 690
Study: 20338067

Group type: EXPERIMENTAL
Intervention: Purell Instant Hand Sanitizer (1.6 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alcare plus (1.6 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2-propanol 60% (v/v) (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Water (1.6 g)
Number of subjects: 15
Study: 18162061

Group type: EXPERIMENTAL
Intervention: 1 mg intracameral triamcinolone acetonide (TA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% eyedrops (6 times per day for 7 days, then 4 times per day for 15 days)
Number of subjects: 60
Study: 12736475

Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic drug infusion for 10 min
Number of subjects: 27

Group type: COMPARATOR
Intervention: Spontaneous termination
Number of subjects: 27
Study: 9583853

Group type: EXPERIMENTAL
Intervention: Treatment for severe malnutrition
Number of subjects: 437
Study: 8586153

Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg once daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 66
Study: 2794184

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison boys (without problems in attention and behavior)
Number of subjects: 25
Study: 324389

Group type: EXPERIMENTAL
Intervention: Josamycin (1.5 g/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Erythromycin (1.0 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31808984

Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral betamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of betamethasone phosphate and betamethasone acetate
Number of subjects: 0
Study: 30724740

Group type: EXPERIMENTAL
Intervention: ikherstel eHealth intervention
Number of subjects: 0
Study: 28619307

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cognitive-behavioral intervention
Number of subjects: 33
Study: 25992536

Group type: EXPERIMENTAL
Intervention: UPCR weighted by estimated daily urine creatinine excretion (eUCr)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard UPCR
Number of subjects: 120
Study: 23937092

Group type: EXPERIMENTAL
Intervention: Blogging (writing about difficulties or free writing; either open or closed to responses)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Blogging (writing about difficulties in blogs open to responses)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Writing a diary on personal computers
Number of subjects: 156

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 156
Study: 21342915

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo and 'tests alone' (non-ZA)
Number of subjects: 22
Study: 19702681

Group type: EXPERIMENTAL
Intervention: Rough-surface implants (TiUnite, n = 45)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hybrid surface implants (Restore, n = 45)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rough-surface with microthreads implants (Hexplant, n = 45)
Number of subjects: 54
Study: 17035507

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15094401

Group type: EXPERIMENTAL
Intervention: Magnitopuncture stimuli on Dazhui (DU14) and Neiguan (PC6) points
Number of subjects: 40

Group type: COMPARATOR
Intervention: Magnitopuncture applied to non-acupuncture points
Number of subjects: 40
Study: 11509226

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg, max 60 g males, 50 g females)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 9624257

Group type: EXPERIMENTAL
Intervention: Tropisetron + Dexamethasone
Number of subjects: 282

Group type: COMPARATOR
Intervention: Tropisetron alone
Number of subjects: 282
Study: 7839102

Group type: EXPERIMENTAL
Intervention: HCV-positive patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Patients with SS
Number of subjects: 32
Study: 3351704

Group type: EXPERIMENTAL
Intervention: Partially modified cow's milk formula
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lactose-free, casein-containing formula
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lactose-free, soy-protein-containing formula
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lactose-free, whey-hydrolysate-containing formula
Number of subjects: 72
Study: 31818632

Group type: EXPERIMENTAL
Intervention: Systematic pain assessment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 117
Study: 31402384

Group type: EXPERIMENTAL
Intervention: RSV fusion (F) protein nanoparticle vaccine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28663633

Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine 0.2% (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg with ropivacaine 0.2% (Group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine 0.2% with dexamethasone 8 mg (Group C)
Number of subjects: 96
Study: 26491204

Group type: EXPERIMENTAL
Intervention: Heparinoid moisturizer applied from 2 weeks following whole-breast radiotherapy until 3 months after completion
Number of subjects: 62

Group type: COMPARATOR
Intervention: No topical moisturizer during the study period
Number of subjects: 62
Study: 23140912

Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: 2-h glucose
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: FPG ≥126 mg/dl and HbA1c ≥6.5%
Number of subjects: 772
Study: 21545942

Group type: EXPERIMENTAL
Intervention: Facilitated percutaneous coronary intervention (fPCI)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 1342
Study: 19153828

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Goserelin plus tamoxifen
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 285

Group type: COMPARATOR
Intervention: No endocrine treatment (Control)
Number of subjects: 285
Study: 17258182

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment for one year
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control group (without simvastatin)
Number of subjects: 806
Study: 15530262

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (100 mg/m(2))
Number of subjects: 119

Group type: COMPARATOR
Intervention: Daily low-dose cisplatin (4 mg/m(2))
Number of subjects: 119
Study: 11245768

Group type: EXPERIMENTAL
Intervention: GAITRite system
Number of subjects: 1
Study: 9749163

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker monotherapy
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: DBP target levels (DBP ≤ 90, DBP ≤ 85, DBP ≤ 80 mmHg)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (75 mg/day)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Stricter blood pressure objective (DBP ≤ 80 mmHg)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: General treatment
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Weight influence
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: DBP and SBP relationship
Number of subjects: 18790
Study: 8168557

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clotrimazole regimen (10 mg twice daily) with Mycostatin (500,000 I.U. four times daily), Benadryl, and Cepacol mouthwash
Number of subjects: 90
Study: 2894934

Group type: EXPERIMENTAL
Intervention: Sphincterotomy (group 2)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Anal stretch (group 1)
Number of subjects: 258
Study: 30410742

Group type: EXPERIMENTAL
Intervention: TrackCare GPS-based smartphone app for continuous location tracking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mother's recall of care-seeking event
Number of subjects: 0
Study: 28314838

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg with prednisone 5 mg twice daily and BEZ235 200 mg twice daily
Number of subjects: 6
Study: 25740751

Group type: COMPARATOR
Intervention: Vitamin A and beta-carotene supplementation (placebo-controlled trial)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Increasing IGF-1 levels
Number of subjects: 589
Study: 24056209

Group type: EXPERIMENTAL
Intervention: Mushroom diet (n=36)
Number of subjects: 73
Study: 22947814

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS) condition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study: 17636399

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment for 2 years
Number of subjects: 564

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 564
Study: 16543298

Group type: EXPERIMENTAL
Intervention: Assertive community treatment team (127 participants)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Community mental health team (124 participants)
Number of subjects: 251
Study: 12630606

Group type: EXPERIMENTAL
Intervention: 30 degrees Reverse Trendelenburg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Supine-Horizontal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 degrees Back Up Fowler
Number of subjects: 26
Study: 11186397

Group type: EXPERIMENTAL
Intervention: Internal fixation using 3 parallel cannulated screws
Number of subjects: 208

Group type: COMPARATOR
Intervention: Uncemented Austin Moore hemiarthroplasty
Number of subjects: 208
Study: 9122104

Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration of the abscess
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Empirical antibiotic treatment for suspected pyogenic abscess
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Routine cytological examination of aspirated abscess material
Number of subjects: 41
Study: 1362746

Group type: EXPERIMENTAL
Intervention: Amoxycillin‐clavulanic acid (2.2 g)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Cefotetan (2 g)
Number of subjects: 221